Gold bars to be exempt from tariffs, White House clarifies
Nxu, Inc., a Delaware-based truck and bus body manufacturer formerly known as Atlis Motor Vehicles Inc., is confronting a potential delisting from the NASDAQ Capital Market. The micro-cap company, currently valued at just $5.07 million, received a notification from NASDAQ on April 1, 2025, indicating its failure to meet the minimum bid price requirement. Despite a reverse stock split executed on March 31, 2025, Nxu did not achieve the necessary bid price of $1.00 per share during the extended compliance period. According to InvestingPro data, the stock has lost 89.2% of its value year-to-date.
The company's troubles began when it was first notified by NASDAQ on April 2, 2024, about its non-compliance with the minimum bid price rule. Nxu was initially given until September 30, 2024, to rectify the situation. An additional grace period extended to March 31, 2025, did not result in compliance either. The reverse stock split, which adjusted the trading of Class A common stock on a 1-for-20 basis, was an attempt to meet the NASDAQ's requirements but ultimately fell short. InvestingPro analysis indicates the company maintains a weak financial health score of 1.33 out of 5, with particularly concerning metrics in profitability and price momentum.
Trading of Nxu's securities is set to be suspended at the start of business on April 10, 2025. The company has requested a hearing to appeal the delisting decision, which is scheduled with NASDAQ's Hearing Panel. However, the request for a hearing will not delay the suspension of trading. The company's stock has shown significant volatility, with a beta of -1.68, indicating strong negative correlation with market movements.
Nxu's management remains hopeful as the stock's closing bid price has been above $1.00 for five consecutive business days following the reverse stock split, but there is no guarantee of regaining compliance for continued listing on the exchange.
This development is based on Nxu's recent SEC filing, reflecting the company's ongoing efforts to meet NASDAQ's listing standards and its intention to present a plan to the Panel to achieve this goal. The outcome of Nxu's appeal and its future on the NASDAQ market remain uncertain at this time. InvestingPro subscribers have access to 20 additional key insights about Nxu, including detailed financial health metrics, valuation analysis, and future growth projections that could be crucial for understanding the company's prospects.
In other recent news, Nxu, Inc. has completed a reverse stock split of its Class A common stock at a ratio of 1-for-20, following approval from stockholders. This corporate action, which took effect on March 31, 2025, aims to consolidate shares and potentially increase the stock's market price. Concurrently, Nxu's stockholders have approved a merger with Verde Bioresins, Inc., which will result in a significant change of control, with pre-merger Verde stockholders owning approximately 95% of the combined entity. The merger, valued at $306.9 million for Verde and $16.2 million for Nxu, is expected to close in March 2025, subject to customary conditions.
Additionally, Nxu announced the appointment of Erin Essenmacher as an independent director to its Board of Directors. Essenmacher will also join the Audit Committee and receive compensation as outlined in a newly established Director Agreement. As part of its strategic initiatives, Nxu is preparing for a rebranding as "Verde Bioresins, Corp." following the merger. The company is also making proportional adjustments to stock options and warrants as part of the reverse stock split. These developments are part of Nxu's broader efforts to enhance its capital structure and governance as it navigates the evolving market landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.